O lume fără cancer. Povestea vitaminei B17

Titlu original: World Without Cancer

Documentarul O lume fără cancer. Povestea vitaminei B17 explorează ideea revoluționară potrivit căreia cancerul este o boală deficitară, o formă gravă de avitaminoză, precum scorbutul sau pelagra, agravată de lipsa unui compus alimentar esențial în dieta omului modern. Această substanță este vitamina B17.

Forma cea mai concentrată și pură, realizată special pentru tratamentele împotriva cancerului, este cunoscută sub numele de Laetrile, o substanță chimică interzisă în prezent în Statele Unite ale Americii. Ideile prezentate în acest film documentar nu sunt aprobate de medicina convențională.

Organizații din SUA, precum Administrația Alimentelor și Medicamentelor (FDA),  Societatea Americană de Cancer și Asociația Medicală Americană, au etichetat cartea pe care se bazează acest film documentar drept „o înșelătorie”. Cu toate acestea, dovezile sunt copleșitoare că vitamina B17 este, în sfârșit, soluția la problema cancerului. De ce a declanșat medicina tradițională un adevărat război asupra acestui tratament revoluționar împotriva cancerului?

Autorul susține că răspunsul ține exclusiv de politică și se bazează pe obiectivele economice și de putere ale celor care controlează sistemul medical. Bazat pe cartea omonimă a lui G. Edward Griffin, O lume fără cancer, se aventurează pe un teritoriu neexplorat și dezvăluie adevăruri șocante despre  modul în care știința a fost subminată pentru a proteja o caracatiță a intereselor comerciale și  politice. Cartea și filmul documentar au potențialul de a genera un impact suficient de puternic pentru a răsturna un imperiu. Și, probabil, vor reuși.


8.49/10 din 37 voturi

Filme similare

5 comentarii la „O lume fără cancer. Povestea vitaminei B17”

  1. What is the theory behind the claim that laetrile is useful in treating cancer?

    Cyanide is thought to be the main anticancer ingredient in laetrile. Two other breakdown products of amygdalin, prunasin (which is similar in structure to Laetrile) and benzaldehyde, may also be cancer cell blockers. The following theories have been proposed to support the use of laetrile for cancer:

    Two of the theories state that the balance of certain enzymes in cancer cells allows laetrile to be toxic to the cancer cells. There is some evidence that normal tissues and malignant tissues do have different amounts of these enzymes.

    Another theory states that cancer is the result of a vitamin deficiency and that laetrile, or “vitamin B-17,” is the missing vitamin needed by the body to restore health. There is currently no evidence that laetrile is needed by the body or that laetrile can act as a vitamin in animals or humans.

    The fourth theory states that the cyanide released by laetrile has a toxic effect that results in killing the cancer cells and stopping them from growing. The theory also states that the damage to the cells causes a boost to the immune system.

    How is laetrile administered?

    Laetrile is given by mouth (orally) as a pill. It can also be given by injection into a vein (intravenously) or muscle. Laetrile is commonly given intravenously over a period of time and then orally as maintenance therapy (treatment given to help extend the benefit of previous therapy).

    Have any preclinical (laboratory or animal) studies been conducted using laetrile?

    Preclinical studies have been done with laetrile either alone or combined with other substances. These studies tested the benefits of laetrile against cancer, the side effects of laetrile treatment, where and how laetrile breaks down in the body, and how laetrile and its breakdown products leave the body. Laboratory and animal studies have shown mixed results on the anticancer effects of laetrile (amygdalin).

    Two animal studies of amygdalin by the National Cancer Institute reported no response when it was given alone or with an enzyme that activates the release of cyanide from amygdalin in the body. The animals had more side effects when the enzyme was given at the same time as the amygdalin.

    Other studies have reported a response to amygdalin:

    One study reported tumor response in mice when amygdalin was given with enzymes and vitamin A, but not when given alone.

    A second study reported that amygdalin caused white blood cells to have an immune response against prostate cancer cells.

    A third study treated tumor cells with amygdalin and the enzyme that activates the release of cyanide. This study reported that tumor cells became more sensitive to radiation.

    Have any clinical trials (research studies with people) of laetrile been conducted?

    No controlled clinical trials (trials that compare groups of patients who receive the new treatment to groups who do not) of laetrile have been reported.

    Although many anecdotal reports (incomplete descriptions of the medical/treatment history of one or more patients) and case reports (detailed reports of the diagnosis, treatment, and follow-up of individual patients) are available, they provide little evidence to support laetrile as a treatment for cancer.

    The following has been reported from case series about the use of laetrile in patients with cancer:

    A case series (a group or series of case reports involving patients who were given similar treatment) of 44 patients treated with laetrile was published in 1953. Most of the patients who showed some improvement also received radiation therapy or anticancer drugs, so it is not known which treatment produced the benefit.

    In another series of case reports published in 1962, 10 patients with metastatic cancer (cancer that has spread from one part of the body to another) were treated with a wide range of doses of intravenous Laetrile. Pain relief was the main reported benefit. Reduced swelling of lymph nodes and decreased tumor size were also reported. Long-term follow-up with these patients was not done, however, so it is not known how long the benefits lasted after treatment.

    Benzaldehyde, which is made when laetrile is broken down by the body, has also been tested for anticancer activity in humans. In two clinical series (case reports of a number of patients who are treated consecutively in a clinic), patients with advanced cancer who had not responded to standard therapy were treated with benzaldehyde. Some patients had a complete response (the disappearance of all signs and symptoms of cancer), while some had a decrease in tumor size. The responses to benzaldehyde lasted as long as the treatment continued. Almost all of the patients had been treated previously with chemotherapy or radiation therapy, but it is not known how soon treatment with benzaldehyde began after the other treatment ended.

    In 1978, the National Cancer Institute (NCI) requested case reports from practitioners who believed their patients were helped by treatment with laetrile. Ninety-three cases were submitted; 67 of these were complete enough to be evaluated. An expert panel concluded that 2 of the 67 patients had complete responses and 4 others had a decrease in tumor size. Based on these 6 cases, NCI sponsored clinical studies with laetrile.

    Findings from only 2 clinical trials with laetrile have been published. These trials, sponsored by NCI, were done in the late 1970s and early 1980s, and did not include a control group for comparison.

    The following has been reported from these 2 clinical trials about the use of laetrile in patients with cancer:

    The first trial, a phase I study, tested doses, schedules, and ways to give amygdalin in 6 cancer patients. Researchers found that amygdalin caused very few side effects when given by mouth or intravenously. Two patients who ate raw almonds while taking amygdalin, however, developed symptoms of cyanide poisoning.

    In 1982, a phase II study with 175 patients looked at which types of cancer might benefit from treatment with amygdalin. Most of the patients in this study had breast, colon, or lung cancer. Amygdalin was given by injection for 21 days, followed by oral maintenance therapy using doses and procedures similar to those in the phase I study. Vitamins and pancreatic enzymes were also given as part of a metabolic therapy program that also included dietary changes. One stomach cancer patient showed a decrease in tumor size, which was maintained for 10 weeks while the patient was on amygdalin therapy. In about half of the patients, cancer had grown at the end of the treatment. Cancer had grown in all patients 7 months after completing treatment. Some patients reported an improvement in their ability to work or do other activities, and other patients said their symptoms improved. These improvements, however, did not last after treatment ended.

    Have any side effects or risks been reported from laetrile?

    The side effects of laetrile treatment are like the signs and symptoms of cyanide poisoning. These include:

    Nausea and vomiting.



    Blue color of the skin due to a lack of oxygen in the blood.

    Liver damage.

    Abnormally low blood pressure.

    Droopy upper eyelid.

    Trouble walking due to damaged nerves.


    Mental confusion.



    The side effects of laetrile appear to depend on the way it is given. Side effects are more severe when laetrile is given by mouth than when it is given by injection. These side effects may be increased by:

    Eating raw almonds or crushed fruit pits.

    Eating certain types of fruits and vegetables, including celery, peaches, bean sprouts, and carrots.

    Taking high doses of vitamin C.

    Is laetrile approved by the FDA for use as a cancer treatment in the United States?

    The U.S. Food and Drug Administration (FDA) has not approved laetrile as a treatment for cancer in the United States. The drug is made and used as a cancer treatment in Mexico.

    Laetrile compounds from Mexico, which is the primary supplier of laetrile, may vary in purity and contents. Products containing bacteria and other substances and products labeled incorrectly have been found.

    Changes To This Summary (06/18/2015)Changes To This Summary (06/18/2015)The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    Changes were made to this summary to match those made to the health professional version.

    About This PDQ Summary

    About This PDQ SummaryAbout PDQ

    Purpose of This Summary

    Reviewers and Updates

    Clinical Trial Information

    Permission to Use This Summary


    Contact UsAbout PDQ

    Physician Data Query (PDQ) is the National Cancer Institute’s (NCI’s) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.

    PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This Summary

    This PDQ cancer information summary has current information about the use of laetrile/amygdalin in the treatment of people with cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.Reviewers and Updates

    Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary („Date Last Modified”) is the date of the most recent change.

    The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Cancer Complementary and Alternative Medicine Editorial Board. Clinical Trial Information

    A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become „standard.” Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

    Clinical trials are listed in PDQ and can be found online at NCI’s website. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237). Permission to Use This Summary

    PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”

    The best way to cite this PDQ summary is:

    National Cancer Institute: PDQ® Laetrile/Amygdalin. Bethesda, MD: National Cancer Institute. Date last modified . Available at: http://www.cancer.gov/about-cancer/treatment/cam/patient/laetrile-pdq. Accessed .

    Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in Visuals Online. Visuals Online is a collection of more than 2,000 scientific images. Disclaimer

    The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.Contact Us

    More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s E-mail Us.

    General CAM Information

    General CAM InformationComplementary and alternative medicine (CAM)—also referred to as integrative medicine—includes a broad range of healing philosophies, approaches, and therapies. A therapy is generally called complementary when it is used in addition to conventional treatments; it is often called alternative when it is used instead of conventional treatment. (Conventional treatments are those that are widely accepted and practiced by the mainstream medical community.) Depending on how they are used, some therapies can be considered either complementary or alternative. Complementary and alternative therapies are used in an effort to prevent illness, reduce stress, prevent or reduce side effects and symptoms, or control or cure disease.

    Unlike conventional treatments for cancer, complementary and alternative therapies are often not covered by insurance companies. Patients should check with their insurance provider to find out about coverage for complementary and alternative therapies.

    Cancer patients considering complementary and alternative therapies should discuss this decision with their doctor, nurse, or pharmacist as they would any therapeutic approach, because some complementary and alternative therapies may interfere with their standard treatment or may be harmful when used with conventional treatment.

    Evaluation of CAM Approaches

    Evaluation of CAM ApproachesIt is important that the same rigorous scientific evaluation used to assess conventional approaches be used to evaluate CAM therapies. The National Cancer Institute and the National Center for Complementary and Integrative Health (NCCIH) are sponsoring a number of clinical trials (research studies) at medical centers to evaluate CAM therapies for cancer.

    Conventional approaches to cancer treatment have generally been studied for safety and effectiveness through a rigorous scientific process that includes clinical trials with large numbers of patients. Less is known about the safety and effectiveness of complementary and alternative methods. Few CAM therapies have undergone rigorous evaluation. A small number of CAM therapies originally considered to be purely alternative approaches are finding a place in cancer treatment—not as cures, but as complementary therapies that may help patients feel better and recover faster. One example is acupuncture. According to a panel of experts at a National Institutes of Health (NIH) in November 1997, acupuncture has been found to be effective in the management of chemotherapy-associated nausea and vomiting and in controlling pain associated with surgery. In contrast, some approaches, such as the use of laetrile, have been studied and found ineffective or potentially harmful.

    The NCI Best Case Series Program which was started in 1991, is one way CAM approaches that are being used in practice are being investigated. The program is overseen by the NCI’s Office of Cancer Complementary and Alternative Medicine (OCCAM). Health care professionals who offer alternative cancer therapies submit their patients’ medical records and related materials to OCCAM. OCCAM conducts a critical review of the materials and develops follow-up research strategies for approaches deemed to warrant NCI-initiated research.

    Questions to Ask Your Health Care Provider About CAM

    Questions to Ask Your Health Care Provider About CAMWhen considering complementary and alternative therapies, patients should ask their health care provider the following questions:

    What side effects can be expected?

    What are the risks associated with this therapy?

    Do the known benefits outweigh the risks?

    What benefits can be expected from this therapy?

    Will the therapy interfere with conventional treatment?

    Is this therapy part of a clinical trial?

    If so, who is sponsoring the trial?

    Will the therapy be covered by health insurance?

    To Learn More About CAM

    To Learn More About CAMNational Center for Complementary and Integrative Health (NCCIH)

    The National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) facilitates research and evaluation of complementary and alternative practices, and provides information about a variety of approaches to health professionals and the public.

    NCCIH Clearinghouse

    Post Office Box 7923 Gaithersburg, MD 20898–7923

    Telephone: 1-888-644-6226 (toll free)

    TTY (for deaf and hard of hearing callers): 1-866-464-3615

    E-mail: info@nccih.nih.gov

    Website: https://nccih.nih.gov

    CAM on PubMed

    NCCIH and the NIH National Library of Medicine (NLM) jointly developed CAM on PubMed, a free and easy-to-use search tool for finding CAM-related journal citations. As a subset of the NLM’s PubMed bibliographic database, CAM on PubMed features more than 230,000 references and abstracts for CAM-related articles from scientific journals. This database also provides links to the websites of over 1,800 journals, allowing users to view full-text articles. (A subscription or other fee may be required to access full-text articles.)

    Office of Cancer Complementary and Alternative Medicine

    The NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) coordinates the activities of the NCI in the area of complementary and alternative medicine (CAM). OCCAM supports CAM cancer research and provides information about cancer-related CAM to health providers and the general public via the NCI website.

    National Cancer Institute (NCI) Cancer Information Service

    U.S. residents may call the NCI Cancer Information Service toll free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 am to 8:00 pm. A trained Cancer Information Specialist is available to answer your questions.

    Food and Drug Administration

    The Food and Drug Administration (FDA) regulates drugs and medical devices to ensure that they are safe and effective.

    Food and Drug Administration

    10903 New Hampshire Avenue

    Silver Spring, MD 20993

    Telephone: 1-888-463-6332 (toll free)

    Website: http://www.fda.gov

    Federal Trade Commission

    The Federal Trade Commission (FTC) enforces consumer protection laws. Publications available from the FTC include:

    Who Cares: Sources of Information About Health Care Products and Services

    Fraudulent Health Claims: Don’t Be Fooled

    Consumer Response Center

    Federal Trade Commission

    600 Pennsylvania Avenue, NW

    Washington, DC 20580

    Telephone: 1-877-FTC-HELP (1-877-382-4357) (toll free)

    TTY (for deaf and hard of hearing callers): 202-326-2502

    Website: http://www.ftc.gov

    < Previous section
    Questions to Ask Your Health Care Provider About CAM

    Updated: June 18, 2015

  2. Da, Americani au găsit antidotul cancerului? Să fie adevărat sau o mare Minciună. Ne întrebăm de ce apare cancerul, de ce apare putrezirea corpului uman. Ce este totuși cancerul? Tumoare malignă constând din înmulțirea excesivă a celulelor cu distrugerea țesuturilor vecine normale; neoplasm; rac. ~ stomacal. Tumoare malignă care distruge țesuturile unor organe interne sau externe; neoplasm; (pop.) rac. Da cum poate fi distrus un program din calculator dumneavoastră? O să ziceți simplu de virușii sau ploșnițe, etc. Da nu avem protecția la virușii activată. Dar în corpul uman lucrurile sunt mult mai complicate. Avem un corp subtil format din cinci învelișuri. Dar cel ma important e Învelișul de Pranayama care este viața din corpurile umane. Spre bătrânețe acest înveliș își pierde puterea și într-un final omul Moare. Deci prima cauză de apariție a cancerului este scăderea Pranei din Învelișul de Pranayama. Deci o tumoare apare în momentul când Prana Shakti pierde controlul asupra unor organe și zone corporale. Atunci în zona respectivă apar ciupercile, bacteriile și viruși care își fac programul lor. Deci ca o concluzie acest tratament medical e bun, dar omul tot va face cancer și va muri. Eu propun curățirea Bulbului Kanda să poată înmagazina în el mai Multă Prana. Închei cu prima cauză, urmând ca altă dată să dau și cauza a doua.

    • Inseamna ca nu ai citit suficient de atent documentarul. Mai citeste-l odata ,, si inca odata. Poate te lamuresti ce interese sunt ca sa nu se renunte la industria farmaceutica megeconsumatoare de fonduri si aducatoare de profituri gigante.


Lasă un comentariu